The follow-up phase II ELIANA trial of 75 patients with CD19 + relapsed/refractory ALL again showed a significant treatment response to tisagenlecleucel, with an overall response rate of 81% [68]. Here, CD19 is linked to acute lymphoblastic leukemia.